SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius ($CELH) is trending as investors anticipate upcoming earnings, with some expecting a strong report due to the Alani Nu acquisition and increased distribution with Pepsi. Community members are actively discussing potential price targets and whether the stock will break out, while also noting pre-earnings manipulation. Bullish sentiment seems high, with many believing $CELH is poised for continued growth in the energy drink market.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending following Q3 earnings and a new $400M AI partnership with Perplexity. Community discussions revolve around the potential for a short squeeze and the long-term implications of AI integration for Snap's growth and profitability, with some expressing skepticism about the company's ability to sustain its gains.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo ($DUOL) is trending as investors debate the impact of AI on its business model after a recent price drop; discussions revolve around whether AI translation tools pose a significant threat to the language learning app's user base and revenue growth. Community members are analyzing the company's growth metrics, subscription numbers, and expansion into new areas like chess amid differing views on its long-term prospects. Some traders are also watching for a potential bounce, citing oversold conditions and strong underlying fundamentals.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health's stock is trending amidst mixed sentiment, with some traders citing positive earnings reports and potential ACA extensions as catalysts for a surge, while others express concern about revenue misses and the impact of subsidy changes; the community is actively debating its near-term trajectory and long-term growth potential within the evolving healthcare landscape, with many focused on potential breakout points.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

Root Inc. is trending amidst mixed sentiment after its recent earnings report, with the community debating whether growth is truly accelerating as guided. Bulls point to undervaluation compared to peers like LMND, while bears cite concerns about profitability and sustainability. Discussion also revolves around potential short squeezes and upcoming catalysts.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

e.l.f. Beauty is trending due to a recent sales forecast that disappointed investors, leading to a stock drop and a Piper Sandler downgrade; however, the retail sector remains optimistic. Community discussions revolve around the company's growth potential, tariff impacts, and whether the sell-off is an overreaction. Some traders are eyeing potential bounce plays, while others express concerns about profitability and consumer spending.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending amid speculation around potential partnerships and analyst upgrades, with Oppenheimer setting a price target of $115. Community discussions revolve around the possibility of a tie-up with OpenAI and the stock's potential to reach new all-time highs, while some traders are wary of resistance levels and recent downgrades.

SuperCom Ltd. engages in the provision of traditional and digital identity solutions. It offers identification, tracking, and security products to government, private and public organization. It operates through the following divisions: e-Gov, Internet of Things (IoT), and Cyber Security. The e-Gov division provides solutions for traditional and biometrics enrollment, personalization, issuance and border control services. The IoT division products and services reliably identify, track, and monitor people or objects in real time, enabling the customers to detect unauthorized movement of people, vehicles, and monitored objects. The Cyber Security division is involved in the comprehensive solutions to protect the organization's sensitive data residing on servers, laptops, and detachable devices. The company was founded by Jack Hasan and Eli Rozen on July 4, 1988 and is headquartered in Tel Aviv, Israel.

SuperCom Ltd

SPCB is gaining attention due to positive due diligence, potential government contracts, and a very small float, leading to discussions of explosive upside. Community members highlight the company's improving financials and strategic positioning in growing markets. The stock is viewed as a high-potential play, with some suggesting even a small ICE contract could trigger a significant price increase.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending as analysts raise price targets following strong Q3 revenue growth driven by its gaming business and early e-commerce platform success. The community is bullish, anticipating further gains and focusing on the potential of the AI-driven Axon platform, with some eyeing a retest of all-time highs, though there are concerns about valuation and regulatory scrutiny.

Fortinet, Inc. provides cybersecurity solutions to a variety of businesses, such as enterprises, communication service providers, government organizations, and small to medium-sized businesses. Its product portfolio includes network security, secure access service edge, enterprise networking, security operations, application security, and operational technology. The company was founded by Ken Xie and Michael Xie in October 2000 and is headquartered in Sunnyvale, CA.

Fortinet Inc

Shares of Fortinet are trending sharply lower, driven by concerns over forward guidance despite a Q3 earnings beat, sparking debates about the company's growth trajectory and market position. The community is actively discussing whether the dip represents a buying opportunity or signals deeper challenges amidst mixed analyst ratings and reports of legal uncertainty. Discussions include the impact of competition and the potential of AI and cloud services to drive future growth for the cybersecurity firm.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Exicure, Inc. (NASDAQ: XCUR) breached their fiduciary duties to shareholders. If you...

Shares of Exicure Inc. surged more than 25% on Thursday, reaching levels last seen over three weeks ago, following the announcement of a strategic acquisition and collaboration deal with South Korea-based GPCR Therapeutics.Exicure revealed it has agreed to purchase all shares of GPCR Therapeutics USA, the California-based subsidiary of GPCR Therapeutics.&nbsp;As part of the agreement, Exicure and GPCR have entered into a licensing and collaboration arrangement to advance and commercialize GPCR-related technologies.While financial terms of the acquisition were not disclosed, Exicure outlined that the deal includes milestone payments to GPCR Therapeutics tied to clinical trial progress, marketing approvals, and net sales achievements.&nbsp;Additionally, Exicure will pay a recurring royalty of at least 10% of net sales derived from the licensed technologies.Retail interest surged after the announcement, with Exicure’s message volume on Stocktwits spiking, placing the ticker among the top 10 trending symbols on the platform.<stembedurl>https://stocktwits.com/topstockalerts/message/601124689</stembedurl><stembedurl>https://stocktwits.com/Pippi_Langstrumpf66/message/601121735</stembedurl>GPCR USA is noted for its work in developing cutting-edge treatments, including Opdivo, a widely used autoimmune disease therapy generating about $10 billion in annual revenue.&nbsp;The company is also behind Yervoy, the first FDA-approved treatment for lung cancer.&nbsp;Currently, GPCR USA is conducting a Phase 2 clinical trial targeting blood cancer patients, focusing on those requiring hematopoietic stem cell transplantation (HSCT) for conditions like multiple myeloma.Exicure’s stock has been a standout performer, gaining 265% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Exicure Stock Soars Over 25% On Acquisition Of GPCR Therapeutics’ U.S. Unit: Retail Chatter Spikes 

GPCR USA is noted for its work in developing cutting-edge treatments, including Opdivo, a widely used autoimmune disease therapy generating about $10 billion in annual revenue.

Equity

Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Exicure, Inc. (Nasdaq: XCUR, the Company, Exicure), today announced that on January 19, 2025, Exicure Inc. (the Company) entered into a Share Purchase Agreement with GPCR Therapeutics Inc., a Korean...

Micro-cap early-stage biotech Exicure, Inc.’s ($XCUR) shares rose sharply in premarket trading on Friday following a deal to acquire a cancer drug pipeline from a South Korean company.The company announcement late Thursday that it had signed a memorandum of understanding with GPCR Therapeutics on Dec. 24 to acquire the latter’s US subsidiary. The agreement also provides for technology transfer and collaborative research on GPCR’s other ongoing drug development pipelines.Chicago-based Exicure said it intends to receive technology transfer for GPCR Therapeutics’ CXCR4 inhibitor, which is in Phase 2 development, along with its related patents and intellectual property.&nbsp;The company views the proposed acquisition as a means to advance as a clinical-stage biotech. It plans to finalize the ongoing clinical trials involving stem cell mobilizers in multiple myeloma patients and prepare clinical studies related to acute myeloid leukemia.&nbsp;Excurire said the market potential for the two blood cancer types is around $1 billion to $2 billion annually.The company also plans to collaborate on R&amp;D in GPCR’s ongoing research in immuno-oncology, fibrosis treatments, and obesity therapies.&nbsp;South Korean drug company GPCR specializes in GPCR (G Protein-Coupled Receptor), representing over one-third of all drug targets. The company has secured target patents around prominent GPCRs such as CXCR4. It possesses multiple pipelines addressing blood cancers and solid tumors, genetic disorders, idiopathic pulmonary fibrosis, and obesity, including ongoing Phase 2 trials in the U.S. for multiple myeloma.&nbsp;Exicure said the deal will be funded from the $14 million capital investments it recently secured in three transactions.&nbsp;In an 8-K filing with the SEC, Exicure said the Nasdaq has notified that the company has met all requirements for continued listing on the exchange.A Stocktwits watcher pointed to the stock's low float and predicted a sharp move on the news.<stembedurl>https://stocktwits.com/SBW_Trades/message/597953319</stembedurl>In premarket trading, Exicure stock was up 8.41% at $18.70 at 7:05 a.m.ET. The stock has gained nearly 500% for the year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/5-media-and-entertainment-and-communication-services-stocks-that-gained-massive-retail-following-on-stocktwits-in-2024/cJO7BR7RjM">5 Media &amp; Entertainment And Communication Services Stocks That Gained Massive Retail Following On Stocktwits in 2024</a>

Woman examining laboratory samples - stock photo | Image source: Getty Images

Exicure Stock Surges On Blood Cancer Portfolio Acquisition Plans, Nasdaq Compliance: Retail Exuberant

Chicago-based Exicure said it intends to receive technology transfer for GPCR Therapeutics’ CXCR4 inhibitor, along with its related patents and intellectual property. 

Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech

Exicure, Inc. (Nasdaq: XCUR, Exicure, the Company), has announced the signing of a Memorandum of Understanding (MOU) with GPCR Therapeutics, Inc. (GPCR Therapeutics) on December 24, 2024, aimed at...

Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Exicure, Inc. (Nasdaq: XCUR, the Company, Exicure), today announced that in connection with the change of control transaction approved by the stockholders at the Special Meeting of the Stockholders...

Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results

Exicure, Inc. (Nasdaq: XCUR, the 'Company') has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated...

Why Exicure Shares Are Trading Higher By Around 180%; Here Are 20 Stocks Moving Premarket

Exicure Stock Is Soaring After The Bell: What's Driving The Action?

Shares of low-float micro-cap stock Exicure are rocketing higher in Wednesday's after-hours session after the company announced that it received an extension from the Nasdaq Hearings Panel.
read more...

Exicure, Inc. Receives Extension from Nasdaq Hearings Panel

Exicure, Inc. (Exicure or the Company) (Nasdaq: XCUR), announced today that on September 17, 2024, the Company received notice that the Nasdaq Hearings Panel (Panel) granted an extension to continue...

Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The firm's product pipeline includes Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Redwood City, CA.

Current Price	$4.10
Prev Close	$4.23
Open	$4.25
Dividend Yield	0.00%
50-Day Moving Average	$4.48
Beta	0.35
Avg. Volume	35,378.78
PE Ratio	-2.42

52-Week High	$36.00
52-Week Low	$2.57
Market Capitalization	$25.9M
EPS (Annual)	-$4.75
Price to Book	2.92
Revenue Per Employee	$71,428.57
Enterprise Value/EBITDA	N/A

XCUR
Exicure Inc

Feed

News

Sentiment

Fundamentals

Info

Latest XCUR News

XCURExicure Inc